Kidney failure and heart related death is a risk for Type 1 diabetes patients with kidney dysfunction.

Effective therapies are need of the hour and can go a long way in retarding the advancement to end stage renal disease in Type 1 diabetes patients with macroalbuminuria.
Dr. Andrzej Krolewski, of the Joslin Diabetes Center and Brigham and Women's Hospital in Boston, said, “New therapies need to be developed including more aggressive or experimental protocols to stop or retard declining renal function, which leads to end-stage renal disease."
Source-Medindia
MEDINDIA




Email










